1276:HKEXJiangsu Hengrui Pharmaceuticals Co.,Ltd Analysis

Jiangsu Hengrui Pharma is trading at HK$64.85, well below its 52‑week high of HK$95.2 but still above the DCF‑derived fair value of HK$33.8, implying a significant valuation gap. The stock sits beneath its 20‑day (HK$66.23), 50‑day (HK$70.18) and 200‑day (HK$72.61) moving averages, signaling a bearish technical backdrop, while the RSI of 44 and a bullish MACD histogram suggest limited short‑term upside. Fundamentally, the company posts strong revenue growth (12.7%), high gross margins (86.3%) and robust cash reserves (HK$40.5 bn) with minimal debt, positioning it for continued expansion.
Recent R&D news on novel Nav1.8 sodium‑channel blockers could unlock new therapeutic markets, adding a growth catalyst. However, a PE of 49x versus an industry average of 26x and a price‑to‑book of 6.4x indicate the stock is currently overvalued, and the high 30‑day volatility (33%) combined with moderate beta (0.52) raise short‑term risk concerns.